RNAi in drug development: Practical considerations

doi:10.1017/CBO9780511546402.030

27 - RNAi in drug development: Practical considerations

Published online by Cambridge University Press: 31 July 2009

Mark A. Kay and

Edited by

Foreword by

Andrew Fire and

Marshall Nirenberg

Show author details

Dmitry Samarsky: Affiliation:
Invitrogen Corporation
Margaret Taylor: Affiliation:
Invitrogen Corporation
Mark A. Kay: Affiliation:
Stanford University School of Medicine, Departments of Pediatrics and Genetics, Program in Human Gene Therapy
Anton P. McCaffrey: Affiliation:
Stanford University School of Medicine, Departments of Pediatrics and Genetics, Program in Human Gene Therapy
Krishnarao Appasani: Affiliation:
GeneExpression Systems, Inc., Massachusetts
Andrew Fire: Affiliation:
Stanford University, California

Book contents

Get access

Summary

Introduction

The development of pharmaceuticals is a complex process that requires a tremendous investment of human and financial resources. In the post-genomic era, drug development has traditionally followed an established protocol that begins with the identification of a new target, proceeds with the identification, optimization and clinical evaluation of small molecule inhibitors of that target and culminates with the successful launch of a new pharmaceutical entity (Figure 27.1). The estimated cost of bringing a new drug to the market place is approximately $900 million over an 8+ year timeframe. RNAi technology can be applied at multiple steps in the drug development process and has the potential to change the pattern of drug development altogether. Indeed, RNAi has been widely employed as a powerful target discovery and validation tool in vitro and is currently being applied in vivo for target validation using whole organisms. In addition several companies are pursuing the clinical development RNAi compounds for the treatment of various diseases.

Mediators of RNAi fall into two main categories: synthetic RNAi compounds, e.g. short interfering RNA (or siRNA) and Invitrogen's STEALTH RNAi™ compounds, that can be delivered exogenously; and RNAi molecules, e.g. short hairpin RNA, or shRNA, that are expressed endogenously from plasmid or viral vectors. Both of these formats have merits as well as limitations, and have application in cultured cells (in vitro) and in whole organisms (in vivo).

Information

Type: Chapter
Information: RNA Interference Technology
From Basic Science to Drug Development
, pp. 384 - 395

DOI: https://doi.org/10.1017/CBO9780511546402.030 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Calegari, F., Haubensak, W., Yang, D., Huttner, W. B. and Buchholz, F. (2002). Tissue-specific RNA interference in postimplantation mouse embryos with endoribonuclease-prepared short interfering RNA. Proceedings of the National Academy of Sciences USA, 99, 14236–14240CrossRef Google Scholar PubMed

Carmeliet, P. and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249–257CrossRef Google Scholar PubMed

Cheng, S. H. and Smith, A. E. (2003). Gene therapy progress and prospects: Gene therapy of lysosomal storage disorders. Gene Therapy, 10, 1275–1281CrossRef Google Scholar PubMed

Davidson, B. L. and Breakefield, X. O. (2003). Viral vectors for gene delivery to the nervous system. Nature Reviews in Neuroscience, 4, 353–364CrossRef Google Scholar

Davis, M. E. (2002). Non-viral gene delivery systems. Current Opinions in Biotechnology, 13, 128–131CrossRef Google Scholar PubMed

Dykxhoorn, D. M., Novina, C. D. and Sharp, P. A. (2003). Killing the messenger: Short RNAs that silence gene expression. Nature Reviews in Molecular Cell Biology, 4, 457–467CrossRef Google Scholar PubMed

Hasuwa, H., Kaseda, K., Einarsdottir, T. and Okabe, M. (2002). Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Letters, 532, 227–230CrossRef Google Scholar PubMed

Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J. and Lowe, S. W. (2003). An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics, 33, 396–400CrossRef Google Scholar PubMed

Herweijer, H. and Wolff, J. A. (2003). Progress and prospects: Naked DNA gene transfer and therapy. Gene Therapy, 10, 453–458CrossRef Google Scholar PubMed

Hu, W. Y., Myers, C. P., Kilzer, J. M., Pfaff, S. L. and Bushman, F. D. (2002). Inhibition of retroviral pathogenesis by RNA interference. Current Biology, 12, 1301–1311CrossRef Google Scholar PubMed

Iyer, M., Berenji, M., Templeton, N. S. and Gambhir, S. S. (2002). Noninvasive imaging of cationic lipid-mediated delivery of optical and PET reporter genes in living mice. Molecular Therapy, 6, 555–562CrossRef Google Scholar PubMed

Kapadia, S. B., Brideau-Andersen, A. and Chisari, F. V. (2003). Interference of hepatitis C virus RNA replication by short interfering RNAs. Proceedings of the National Academy of Sciences USA, 100, 2014–2018CrossRef Google Scholar PubMed

Khvorova, A., Reynolds, A. and Jayasena, S. D. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell, 99, 133–141Google Scholar

Lewis, D. L., Hagstrom, J. E., Loomis, A. G., Wolff, J. A. and Herweijer, H. (2002). Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nature Genetics, 32, 107–108CrossRef Google Scholar PubMed

Lundstrom, K. (2003). Latest development in viral vectors for gene therapy. Trends in Biotechnology, 21, 117–122CrossRef Google Scholar PubMed

McCaffrey, A. P., Meuse, L., Pham, T. T., Conklin, D. S., Hannon, G. J. and Kay, M. A. (2002). RNA interference in adult mice. Nature, 418, 38–39CrossRef Google Scholar PubMed

McCaffrey, A. P., Nakai, H., Pandey, K., Huang, Z., Salazar, F. H., Xu, H., Wieland, S. F., Marion, P. L. and Kay, M. A. (2003). Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology, 21, 639–644CrossRef Google Scholar PubMed

Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L. and Paulson, H. L. (2003). Allele-specific silencing of dominant disease genes. Proceedings of the National Academy of Sciences USA, 100, 7195–7200CrossRef Google Scholar PubMed

Ozaki, I., Zern, M. A., Liu, S., Wei, D. L., Pomerantz, R. J. and Duan, L. (1999). Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells. Journal of Hepatology, 31, 53–60CrossRef Google Scholar PubMed

Pekarik, V., Bourikas, D., Miglino, N., Joset, P., Preiswerk, S. and Stoeckli, E. T. (2003). Screening for gene function in chicken embryo using RNAi and electroporation. Nature Biotechnology, 21, 93–96CrossRef Google Scholar PubMed

Randall, G., Grakoui, A. and Rice, C. M. (2003). Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proceedings of the National Academy of Sciences USA, 100, 235–240CrossRef Google Scholar PubMed

Reich, S. J., Fosnot, J., Kuroki, A., Tang, W., Yang, X., Maguire, A. M., Bennett, J. and Tolentino, M. J. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Molecular Vision, 9, 210–216Google Scholar PubMed

Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Ihrig, M. M., McManus, M. T., Gertler, F. B., Scott, M. L. and Van Parijs, L. (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics, 33, 401–406CrossRef Google Scholar PubMed

Schwartz, D. S., Hütvagner, G., Du, T., Xu, Z., Aronin, N. and Zamore, P. D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 199–208CrossRef Google Scholar

Seo, M. Y., Abrignani, S., Houghton, M. and Han, J. H. (2003). Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. Journal of Virology, 77, 810–812CrossRef Google Scholar PubMed

Song, E., Lee, S. K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P. and Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Medicine, 9, 347–351CrossRef Google Scholar PubMed

Svoboda, P., Stein, P., Hayashi, H. and Schultz, R. M. (2000). Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference. Development, 127, 4147–4156Google Scholar PubMed

Wianny, F. and Zernicka-Goetz, M. (2000). Specific interference with gene function by double-stranded RNA in early mouse development. Nature Cell Biology, 2, 70–75CrossRef Google Scholar PubMed

Xia, H., Mao, Q., Paulson, H. L. and Davidson, B. L. (2002). siRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnology, 20, 1006–1010CrossRef Google Scholar PubMed

Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S. C. and Coukos, G. (2003). Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochemical and Biophysical Research Communications, 303, 1169–1178CrossRef Google Scholar

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.